PRECISE LBCL: Precision Treatment Readiness Through Comprehensive Genomic Sequencing in 1st Line LBCL
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07829445
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Comprehensive Genomic
- LBCL
- Precision Treatment
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Standard of Care (SOC) — OTHERStandard of care
Study Details
To determine whether special laboratory tests, called genomic sequencing, can identify specific subtypes of LBCL and provide information that may help guide treatment decisions.
Key Dates
- First listed
- Sep 21, 2026
- Start date
- Feb 25, 2027
- Status verified
- Sep 2026
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2029
Study Design
- Enrollment
- 60 participants (estimated)
Arms
- Arm: ABC_Subtype
- Arm: DZsig_Subtype
- Arm: Other GCB_Subtype
Primary Outcome Measure
Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]
Central Contacts
- Dai Chihara, MD713-563-4354
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | Dai Chihara, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site